Compare Heron Therapeutics Inc (HRTX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.16B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is far larger — about 42.7× Heron Therapeutics Inc's market cap, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| HRTX | SPHD | |
|---|---|---|
Market Cap | $74.04M | $3.16B |
Volume | 3,668,095 | 1,245,780 |
Sector | Health | — |
52-Week High | $1.49 | $53.55 |
52-Week Low | $0.27 | $46.96 |
Typical Hold Time | 35 Days | 125 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SPHD trades at $48.19, down 0.58% with a bearish technical outlook showing 17 sell signals versus 4 buy signals. The ETF maintains its high-dividend focus with recent payouts of $0.20-$0.21, though financial ratios remain unavailable. Technical indicators show oversold conditions with RSI at 6.33-14.37 levels while moving averages signal continued downward pressure.
The ETF faces headwinds from underperformance concerns versus peers like SCHD, with media highlighting decade-long return disparities. While monthly dividends appeal to income investors, the lack of quality screening in stock selection poses yield trap risks. Current sentiment leans cautious as analysts question the fund's total return potential amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
